Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Monday, November 23, 2009, 3:23AM ET - U.S. Markets open in 6 hours and 7 minutes. Dow Down 0.14% Nasdaq  0.00%
Insite Vision Inc. (INSV.OB)On Nov 20: 0.39   0.00 (0.00%)  
MORE ON INSV.OB
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
Insite Vision Inc.
965 Atlantic Avenue
Alameda, CA 94501
United States - Map
Phone: 510-865-8800
Fax: 510-865-5700
Web Site: http://www.insitevision.com

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Delivery
Full Time Employees:34

BUSINESS SUMMARY 
InSite Vision Incorporated operates as an ophthalmic product development company in the United States. It engages in the development and commercialization of ophthalmic pharmaceutical products based on DuraSite drug delivery technology. The company offers AzaSite for the treatment of bacterial conjunctivitis. It develops ISV-502, which completed Phase III (a) clinical trial for the treatment of blepharoconjunctivitis, an infection of the eyelid and the conjunctiva, as well as other ophthalmic infections; and ISV-405, a preclinical development candidate for the treatment of ocular infection. InSite Vision Incorporated has collaborative, licensing, and service agreements with Shin Poong Pharm Co., Ltd.; Bioceutica S.A.; Biem Pharmaceuticals; Essex Bio-Technology; Pfizer Inc. and Pfizer Products, Inc.; and Inspire Pharmaceuticals, Inc.; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. The company was founded in 1986 and is based in Alameda, California.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on Insite Vision Inc.


    CORPORATE GOVERNANCE 
    Insite Vision Inc.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 71.2% of CGQ Universe companies and 47% of Health Care Equipment & Services companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Mr. Louis C. Drapeau C.P.A., M.B.A., 65
    Interim Chief Exec. Officer, Chief Financial Officer and VP
    $ 270.00K $ 0
    Dr. Lyle M. Bowman Ph.D., 60
    VP of Devel. and Sec.
    $ 311.00K $ 0
    Mr. David F. Heniges , 64
    VP and Gen. Mang. of Commercial Opportunities
    $ 302.00K $ 0
    Mr. Surendra Patel , 54
    VP of Operations
    N/A N/A
    Dr. Kamran Hosseini M.D., Ph.D., 44
    Chief Medical Officer and VP of Clinical Affairs
    N/A N/A
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis